This article discusses the notion of emergent concerned groups and explores how these groups contribute to shaping the relations between technoscience, politics, and economic markets. The first part presents the case of the French Association of patients suffering from muscular dystrophies. This history suggests that under certain conditions, emergent concerned groups are able to impose a new form of articulation between scientific research and political identities by directly linking the issues of research content and results to that of their place in the collective. The second part argues that the evolution of economic markets, combined with that of science and technology, leads to a multiplication of those emergent concerned groups. The study of the conditions under which these emergent groups become legitimate stakeholders as well as the analysis of their impact on market organization and technoscientific institutions are key research topics for the near future.
Abbot, A.2001. Time matters. Chicago: Chicago University Press.
2.
Abraham, J., and G. Lewis.2002. Citizenship, medical expertise and the capitalist regulatory state in Europe. Sociology36:67-88.
3.
Amin, A., and P. Cohendet.2004. Architectures of knowledge: Firms, capabilities and communities. Oxford, UK: Oxford University Press.
4.
Barataud, B.1992. Au nom de nos enfants. Paris: J'ai lu.
5.
Barral, C., I. Gobatto, B. Maffioli, and I. Spaak.1991. Naissance et développement du mouvement de lutte contre les maladies neuro-musculaires en France (1958-1982). Évry, France: AFM (Association Française contre les Myopathies)/CTNERHI (Centre Technique National d'Etudes et de Recherches sur les Handicaps et les Inadaptations).
6.
Bonneuil, C., and F. Thomas.2004. Du maïs hybride aux OGM. Un demi-siècle de génétique et d'amélioration des plantes à l'INRA. In Actes du Colloque. L'amélioration des plantes, continuités et ruptures, edited by P. Boistard, C. Sabbagh, and I. Savini, 42-53. Paris : INRA.
7.
Brown, P.1992. Popular epidemiology and toxic waste contamination: Lay and professional ways of knowing. Journal of Health and Social Behaviour33:267-81.
8.
Brown, P., S. McCormick, B. Mayer, S. Zavetovski, R. Morello-Frosch, R. Gasior Altman, and L. Senier.2006. “A lab of our own”: Environmental causation of breast cancer and challenges to the dominant epidemiological paradigm. Science, Technology, & Human Values31:499-536.
9.
Callon, M.1980a. Struggles and negotiations to decide what is problematic and what is not: The socio-logics of translation. In The social process of scientific investigation, edited by K. Knorr, R. Krohn, and R. Whitley, 197-220. Dordrecht, Netherlands: D. Reidel.
10.
———. 1980b. The state and technical innovation: A case study of the electrical vehicle in France. Research Policy9:358-76.
11.
———. 1992. The dynamics of techno-economic networks. In Technological change and company strategies, edited by R. Coombs, P. Saviotti, and V. Walsh, 72-102. London: Academic Press.
12.
———. 1994. Is science a public good? Science, Technology, & Human Values19:395-424.
13.
———. 1995. Technological conception and adoption network. Lessons for the CTA practitioner. In Managing technology in society: The approach of constructive technology assessment, edited by A. Rip, T. J. Misa , and J. Schot, 307-30. London : Pinter.
14.
———, ed. 1998. The laws of the markets. London: Blackwell.
15.
———. 2003. The increasing involvement of concerned groups in R&D policies: What lessons for public powers? In Science and innovation: Rethinking the rationales for funding and governance, edited by A. Geuna, A. Salter, and W. E. Steinmueller, 30-68. Cheltenham , UK: Edward Elgar.
16.
———. 2006. Regards croisés sur l'AFMhttp//www.afm20ansdactions.org/ewb_pages/r/regards?synthese.php (accessed November 28, 2007)
17.
———. 2007. What does it mean to say that economics is performative? In How economists make markets: The performativity of economics , edited by D. MacKenzie, F. Muniesa, and L. Siu , 311-57. Princeton, NJ: Princeton University Press.
18.
Callon, M., and K. Caliskan.2007. New directions in the anthropology of markets. In preparation, Ecole des mines de Paris.
19.
Callon, M., and P. Cohendet , eds. 1999. Réseau et coordination. Paris: Economica.
20.
Callon, M., P. Lascoumes, and Y. Barthe.2001. Agir dans un monde incertain. Essai sur la démocratie technique. Paris: Le Seuil.
21.
Callon, M., and J. Law.1982. On interests and their transformation: Enrollment and counter-enrollment. Social Studies of Science12:615-25.
22.
Callon, M., C. Méadel, and V. Rabeharisoa.2002. The economy of qualities. Economy and Society31 (2): 194-217.
23.
Callon, M., and F. Muniesa.2005. Economic markets as calculative collective devices. Organization Studies26:1129-50.
24.
Callon, M., and V. Rabeharisoa.2004. Gino's lesson on humanity. Genetics, mutual entanglements and the sociologist's role. Economy and Society33 (1): 1-27.
25.
Cardon, D., and J.-P. Heurtin.1999. Les formats de la générositéTrois explorations du Téléthon. Réseaux17 (95): 15-105.
26.
Dasgupta, P., and P. David.1994. Toward a new economics of science. Research Policy23:487-521.
27.
David, P.1986. Narrow windows, blind giants and angry orphans: The dynamics of systems rivalries and dilemmas of technology policy Working Paper 10, Technological Innovation Project.
28.
DeBresson, C., and F. Amesse.1991. Networks of innovators: A review and an introduction to the issue. Research Policy20:363-80.
29.
Dewey, J.1916. Essays in experimental logic. New York : Dover.
30.
Epstein, S.1995. The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials. Science, Technology, & Human Values20:408-37.
31.
———. Forthcoming. Patient groups and health movements. In New handbook of science and technology studies, edited by E. J. Hackett, O. Amstermdamska , M. Lynch, and J. Wacjman.Cambridge, MA: MIT Press.
32.
Foucault, M.1994. Dits et ecrits1954-1988. Paris: Gallimard.
33.
Fox-Keller, E.1996. Refiguring life: Metaphors of twentieth-century biology . New York: Columbia University Press.
34.
Garud, R., and P. Karnoe.2003. Bricolage vs. breakthrough: Distributed and embedded agency in technology entrepreneurship. Research Policy32:277-300.
35.
Givernaud, N., and J.-F. Picard.2001. Histoire de la génomique en France. Paris: CNRS. http://picardp1.ivry.cnrs.fr/Histgen.html (accessed November 28, 2007).
36.
Granovetter, M., and P. McGuire.1998. The making of an industry: Electricity in the United States. In The laws of the markets, edited by M. Callon, 147-73. Oxford, UK: Blackwell.
37.
Guston, D.2000. Between politics and science: Assuring the integrity and productivity of research. Cambridge, UK: Cambridge University Press.
38.
Heath, D., R. Rapp, and K.S. Taussig.2004. Genetic citizenship. In Companion to the anthropology of politics, edited by D. Nugent and J. Vincent, 152-67. London : Basil Blackwell.
39.
Hecht, G.1998. The radiance of France: Nuclear power and national identity after World War II. Cambridge, MA: MIT Press.
40.
Hess, D.2005. Technology- and product-oriented movements: Approximating social movement. Science, Technology, & Human Values30:513-35.
41.
Hess, D., S. Breyman, N. Campbell, and B. Martin.Forthcoming. Science, technology, and social movements . In New handbook of science and technology studies, edited by E. J. Hackett, O. Amstermdamska, M. Lynch, and J. Wacjman.Cambridge, MA : MIT Press.
42.
Jasanoff, S.2003. Technologies of humility: Citizen participation in governing science. Minerva41 (3): 223-44.
43.
Joly, P.-B., and B. Hervieu.2003. La marchandisation du vivant: Pour une mutualisation des recherches en génomiqueFuturibles292:5-29.
44.
Kahane, B.2000. Impact de l'intervention de l'AFM sur la stratégie du département Sciences de la Vie du CNRS. In Cahier de la Direction de l'Evaluation et des Audits (CNRS). Paris: CNRS.
45.
Kaji, M.2004. Expert and citizen participation in pollution control: The case of Toyama cadmium poisoning (itai-itai disease) in Japan. Paper presented at the 4S-EASST Conference, Paris.
46.
Kepper, Y.1988. Les enfants myopathes. Paris: Fayard.
47.
Kupiec, J.-J., and P. Sonigo.2003. Ni Dieu, ni gène. Pour une autre théorie de l'hérédité. Paris: Le Seuil.
48.
Lakoff, A. Forthcoming. The right patients for the drug: Pharmaceutical circuits and the codification of illness. In New handbook of science and technology studies, edited by E. J. Hackett , O. Amstermdamska, M. Lynch, and J. Wacjman.Cambridge, MA: MIT Press.
49.
MacKenzie, D.2006. An engine, not a camera. How financial models shape markets . Cambridge, MA: MIT Press.
50.
Miller, P. and N. Rose.2008. Governing the present. Administering economic, social and personal life. Cambridge, UK: Polity Press.
51.
Nunes, J.A.2003. The uncertain and the unruly: Complexity and singularity in biomedicine and public health Oficina do CES 184.
52.
Pestre, D.2003. Science, argent et politique. Un essai d'interprétation . Paris: INRA Editions.
53.
Pignarre, P.2001. Comment la dépression est devenue une épidémie. Paris: La Découverte.
54.
———. 2003. Le grand secret de l'industrie pharmaceutique. Paris: La Découverte.
55.
Rabeharisoa, V.2006. From representation to mediation: The shaping of collective mobilization on muscular distrophy in France. Social Science & Medicine62:564-76.
56.
Rabeharisoa, V., and M. Callon.1999. Le pouvoir des malades: l'Association française contre les myopathies & la recherche. Paris : Presses de l'Ecole des mines de Paris.
57.
———. 2000. De la médiation, ou les enjeux d'un nouveau métier dans le secteur de la prise en charge des personnes handicapées. Contrastes. Enfance et Handicap13:217-35.
58.
Rabinow, P.1996. Essays on the anthropology of reason. Princeton, NJ: Princeton University Press.
59.
———. 2004. Anthropos today: Reflections on modern equipment. Princeton, NJ: Princeton University Press.
60.
Rémondet, M.2004. Le laboratoire de thérapie génique à l'épreuve de la clinique: Sociologie d'une expérimentation médicale PhD diss., Ecole des mines de Paris, France.
61.
Rose, N., and C. Novas.2005. Biological citizenship. In Global assemblages: Technology, politics, and ethics as anthropological problems , edited by A. Ong and S. J. Collier, 439-63. Malden, MA: Blackwell.
62.
Sampat, B.N.2006. Patenting and US academic research in the 20th century: The world before and after Bayh-Dole. Research Policy35:772-89.
63.
Strathern, M.1999. What is intellectual property after? In Actor network theory and after, edited by J. Law and J. Hassard, 156-80. Oxford , UK: Blackwell.
64.
Tambourin, P.2005. Les grands instruments de la biologie moléculaire, prémices de la médecine de demain. La Revue pour l'Histoire du CNRS12:18-29.
65.
von Hippel, E.2004. Democratizing innovation. Cambridge, MA: MIT Press.
66.
von Krogh, G., and E. von Hippel.2003. Special issue on open source development. ResearchPolicy32:1149-57.
67.
Weiner, C.M.2006. Patients and professional constructions of hypercholesterolaemia and heart disease: Testing the limits of the geneticisation thesis. PhD diss ., University of Nottingham, UK.
68.
Winance, M.2001. Thèse et prothèse. Le processus d'habilitation comme fabrication de la personne PhD diss., Ecole des mines de Paris, France.
